Allele Frequencies of Tissue Factor Pathway Inhibitor Polymorphisms in African-American, Hispanic and Caucasian Populations

• References

• 1 Girard T-J, Warren L-A, Novotny W-F. et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1998; 338: 518-20.
• 2 Bajaj M-S, Birktoft J-J, Steer S-A, Bajaj S-P. Structure and biology of tissue factor pathway inhibitor. Review. Thromb Haemost 2001; 86: 959-72.
• 3 Osterud B, Bajaj M-S, Bajaj S-P. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995; 73: 873-5.
• 4 Moatti D, Seknadji P, Galand C. et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects. Arterioscler Thromb Vasc Biol 1999; 19: 862-9.
• 5 Amini-Nekoo A, Futers T-S, Moia M, Mannucci P-M, Grant P-J, Ariens R-A-S. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. British J Haematol 2001; 113: 537-43.
• 6 Kleesiek K, Schmidt M, Gotting C. et al. The 536→C transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
• 7 Paciaroni K, Rossi E, Bazzan M, Ireland H, De Stefano V. Prevalence of the C536T mutation in the tissue factor pathway inhibitor (TFPI) gene among patients with venous thrombotic disease. Thromb Haemost 2001; 85: 938-9.
• 8 Gonzales-Conejero R, Lozano M-L, Corral J, Martinez C, Vicente V. The TFPI 536 C→T mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemost 2000; 83: 787-8.
• 9 Hessner M-J, Luhm R-A. The C536T transition in the tissue factor pathway inhibitor (TFPI) gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden. Thromb Haemost 2000; 84: 724-5.